Search

Your search keyword '"Logar D"' showing total 38 results
Start Over Author "Logar D"
38 results on '"Logar D"'

3. Leflunomide and hypertension

Author

Rozman, B, Praprotnik, S, Logar, D, Tomšič, M, Hojnik, M, Kos-Golja, M, Accetto, R, and Dolenc, P

Published
2002

5. Leflunomide and hypertension. (Letters)

Author

Rozman, B, Praprotnik, S, Logar, D, Tomsic, M, Hojnik, M, Kos-Golja, M, Accetto, R, and Dolenc, P

Subjects
Leflunomide -- Complications and side effects, Rheumatoid arthritis -- Drug therapy -- Risk factors -- Complications and side effects, Hypertension -- Risk factors -- Complications and side effects -- Drug therapy, Health
Abstract

Leflunomide is a new isoxazole drug with disease modifying properties for the treatment of rheumatoid arthritis (RA). Hypertension has been mentioned as a common side effect of the treatment. It [...]

Published
2002

6. IX Eular Workshop for Rheumatology Research: Molecular biology of autoantigens, autoantibodies and immunopeptides. Vienna, Austria, March 9–12, 1989

Author

Fournier, C., Texier, B., Chiocchia, G., Boissier, M. C., Herbage, D., Brown, C. M. S., Zyberk, C. Plater, Maini, R. N., Palacios, A., Sieper, J., Heinegard, D., Panayi, G. S., Gentric, A., Mackenzie, L., Lydyard, P. M., Youinou, P., Menzel, E. J., Kaik, B., Sykulev, Yu. K., Guschin, A. Je., Vasiljev, V. I., Ostreiko, K. K., Yeronina, T. V., Tumanova, I. A., Moynier, M., Abderrazik, M., Combe, B., Rucheton, M., Brochier, J., Tuomi, T., Palosuo, T., Heliövaara, M., Aho, K., McHugh, N. J., James, I. E., Kallenberg, C. G. M., Tervaert, J. W. Cohen, Goldschmeding, R., Von Dem Borne, A. E. G. K. R., Bouanani, M., Piechaczyk, M., Pau, B., Bastide, M., Le Page, S., Williams, W., Parkhouse, D., Cambridge, G., Isenberg, D. A., Nimmegeers, J., De Keyser, F., Verbruggen, G., Veys, E. M., Walravens M. J. F., Verdeyen I., Vandepol B., Cortens W., Schatteman, L., Goethals, K., Wu, D. -H., Tavoni, A., Neri, R., Garzelli, C., Vitali, C., Bombardieri, S., Logar, D., Kveder, T., Dobovisek, J., Rozman, B., Menard, H. A., Boire, G., Lopez-Longo, F. J., Masson, Ch., Lapointe, S., Clair, E. W. St., Zerva, L., Moutsopoulos, H. M., Keene, J. D., Pisetsky, D. S., Van Dam, A. P., Cuypers, H. T. M., Winkel, I., Smeenk, R. J. T., Taylor, D., Valente, E., Foster, J. P., Williams, D. G., Stocks, M. R., Caporali, R., De Gennaro, F., Cerino, A., Cobianchi, F., Astaldi-Ricotti, G. C. B., Montecucco, C., Habets, W., Sillekens, P. T. G., Hoet, M. H., McAllister, G., Lerner, M. R., Van Venrooij, W. J., Habets, W. J., Van Der Kemp, A., De Jong, B., Scarpa, R., Pucino, A., Di Girolamo, C., della Valle, G., Larizza, G., Casiere, D., Oriente, P., Paimela, L., Palvimo, J., Kurki, P., Hassfeld, W., Steiner, G., Graninger, W., Smolen, J. S., Lopez-Longo, E. J., Larose, A., Hoet, R., Zewald, R., Smeenk, R., Brinkman, K., Van Den Brink, H., Westgeest, A., Huss, R., Krapf, E. F., Herrmann, M., Leitmann, W., Kalden, J. R., Merétey, K., Cebecauer, L., Böhm, U., Kozakova, D., Brózik, M., Temesvári, P., Nagy, L., Bozic, B., Stegnar, M., Vene, N., Peternel, P., Giuggioli, C., Monti, P., Rossi, G., Ferri, C., Chiellini, S., Baboonian, C., Venables, P. J. W., Roffe, L., Booth, J., Krapf, F., Abuljadayel, I., Ebringer, A., Cox, N. L., Brand, S. R., McIntosh, D. P., Bernstein, R. M., Van Den Broek, M. F., Van Bruggen, M. C. J., Smetsers, T., Kuyer, P., Van De Putte, L., Van Den Berg, W. B., Toivanen, A., Jalkanen, S., Lahesmaa-Rantala, R., Isomäki, O., Pekkola-Heino, K., Merilahti-Palo Saario, R., Von Essen, R., Isomäki, H., Granfors, K., Gaston, J. S. H., Life, P. F., Bailey, L., Bacon, P. A., Khalafpour, S., Wilson, C., Awad, J., Toivanen, P., Saario, R., Skurnik, M., Van Der Straeten, C., Mielants, H., Gazic, M., Hartung, K., Riedel, T., Stannat, S., Specker, Ch., Röther, E., Pirner, K., Schendel, D., Baur, M., Corvetta, A., Peter, H. H., Lakomek, H. J., Deicher, H., Andonopoulos, A. P., Papasteriades, C. A., Drosos, A. A., Dimou, G. S., Shattles, W., Venables, P., Charles, P. J., Markwick, J. R., Venables, P. J., Galeazzi, M., Lulli, P., Tuzi, T., Cappellacci, S., Morellini, M., Trabace, S., Cutrupi, F., Sorrentino, R., Botti, S., Iannicola, C., Costanzi, S., Tosi, R., Gospodinoff, A., Eliaou, J. F., Humbert, H., Balaguer, P., Nicolas, J. C., Sany, J., Clot, J., Sakkas, L. I., Bird, H., Welsh, K. I., Pitzalis, C., Kingsley, G., Haskard, D., Vischer, T. L., Bas, S., Werner-Favre, C., Wohlwend, D., Zubler, R. H., Afeltra, A., De Pita, O., Basso, P., Pietrucci, A., Ferri, G. M., Bonomo, L., Gerli, R., Cernetti, C., Bertotto, A., Agea, E., Arcangeli, C., Lanfrancone, L., Rambotti, P., Crupi, S., Baglioni, A., Spinozzi, F., Papazoglou, S., Skoumi, D., Athanasiou, P., Iliopoulos, A., Stavropoulou, A., Kontomerkos, T., Hendrich, G., Kuipers, J. G., Hammer, M., Schmidt, R. E., Manoussakis, M. N., Germandis, G., Zerva, L. V., Siouna-Fatourou, H. J., Katsikis, P. D., Mavridis, A., Toubert, A., Sadouk, M., de la Tour, B., Vaquero, C., Amor, B., Miossec, P., Naviliat, M., Cretien, I., Banchereau, J., Graninger, P., Aschauer, B., Sinski, A., Smolen, J., Krutmann, J., Kirnbauer, R., Köck, A., Schwarz, T., May, L. T., Sehgal, P. B., Luger, T. A., Field, M., Chu, C. Q., Feldmann, M., Wilbrink, B., Nietfeld, J. J., Helle, M., Boeije, L. C. M., Van Roy, J. L. A. M., Den Otter, W., Aarden, L. A., Huber-Bruning, O., Malejczyk, J., Urbanski, A., Malejczyk, M., Karbowski, A., Völker, W., Feige, U., Otter, W. Den, Malfait, A. M., Wieme, N., Gyselbrecht, L., Van de Loo, A. A. J., Van Lent, P. L. E. M., Haskard, D. O., Wellicome, S., Lanchbury, J., Thornhill, M., Krutmann, K., Gschnait, F., Yaron, M., Yaron, I., Dayer, J. -M., Bleiberg, I., Meyer, F. -A., Maury, C. P. J., Teppo, A. -M., Salo, E., Pelkonen, P., Malfait, A., Cochez, Ph., Gruschwitz, M., Müller, P. U., Wick, G., Madhok, R., Wilson, R., Frame, M., Thompson, J., Sturrock, R. D., Partsch, G., Matucci-Cerinic, M., Marabini, S., Jantsch, S., Neumüller, J., Eberl, R., van Beuningen, H. M., Arntz, O. J., Zlabinger, G. J., Steffen, C., Brand, H. S., Van Kampen, G. P. J., De Koning, M. H. M. T., Kiljan, E., Van Der Korst, J. K., Gemmell, C. G., Swaak, A. J. G., Van Rooyen, A., Hall, N. D., Woolf, A. D., Kantharia, B., Maymo, J., Blake, D. R., Goulding, N. J., Maddison, P. J., Munthe, E., Berntzen, H. B., Fagerhol, M., Mathieu, A., Pala, R., Contu, L., Cirillo, R., Garau, P., Nurchis, P., Viberti, G. C., Meyer, O., Zenklusen, C., Le Thi Huong Du, Z., Gaudouen, C., Mery, J. Ph., Ronco, P., Kahn, M. F., Rasmussen, N., Szpirt, W., Thomsen, B., Humbel, R. L., Ter Borg, E. J., Horst, G., Hummel, E., Limburg, P. C., Aeschilmann, A., Bourgeois, P., De Rooij, D. J., Van de Putte, L. B. A., Verbeek, L., Farinaro, C., Infranzi, E., Couret, M., Ackerman, C., De Vlam, K., Carapic, V., Carapic, D., Annefeld, M., Erne, B., Rosenwasser, L. J., Pazoles, C. J., Otterness, I. G., Hanson, D. C., McDonald, B., Loose, L. D., Dougados, M., Machold, K. P., Wiesenberg-Böttcher, I., Wanner, K., Pignat, W., Altmann, H., Tuschl, H., Bröll, H., Balestrieri, G., Tincani, A., Cattaneo, R., Bertoli, M. T., Martinelli, M., Allegro, F., Meroni, P. L., Balesini, G., Aichinger, G., Schlögl, E., Huber, Ch., Shoenfeld, Y., Fleishmaker, E., Mendlovic, S., Mozes, E., Blank, M., Talal, N., Hogervorst, E. J. M., Van Eden, W., Van Der Zee, R., Psychos, D., Dimou, G., Stefanaki-Nikou, S., Papadimitriou, C. S., Settas, L., Alexiou, P., Dimitriadis, G., Mataftsi, E., Soliou, E., Tourkantonis, A., Babic, M., Jeurissen, M. E. C., and Boerbooms, A. MTh

Published
1989
Full Text
View/download PDF

8. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (ESCISIT)

Author

Swaak, AJG van de Brink, H Smeenk, RJT Manger, K Kalden, JR Tosi, S Marchesoni, A Domljan, Z Rozman, B Logar, D Pokorny, G Kovacs, L Kovacs, A Vlachoyiannopoulos, PG and Moutsopoulos, HM Chwalinska-Sadowska, H Dratwianka, B and Kiss, E Cikes, N Anic, B Schneider, M Fischer, R and Bombardieri, S Mosca, M Graninger, W Smolen, JS Study Grp Incomplete SLE & SLE D

Subjects
immune system diseases, skin and connective tissue diseases
Abstract

Objective. Patients characterized with antinuclear antibodies (ANA) and disease symptoms related to one organ system can be described as having incomplete systemic lupus erythematosus (SLE). Thr aim of this multicentre study was to describe the outcome of these so-called incomplete SLE patients. Two aspects of the outcome were studied: (i) the disease course, defined by the presence or absence of clinical symptoms: and (ii) the number of patients that eventually developed full SLE. Methods. Outcome parameters were the ACR criteria, the SLE: disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM) and the requirement for treatment. In 10 European rheumatology centres, patients who had been evaluated in the last 3 months of 1994 and had been diagnosed as having incomplete SLE on clinical grounds for at least yr were included in the study. All 122, patients who were included in the study were evaluated annually during 3 yr of follow-up. Results. Our results are confined to a patient cohort defined by disease duration of at least yr, being under clinical care at the different centres in Europe. These patients showed disease activity that was related mostly to symptoms of the skin and the musculoskeletal system, and leucocytopenia. During the follow-up, low doses of prednisolone were still being prescribed in 43%, of the patients. On recruitment to the study, 22 of the 112 incomplete SLE patients already fulfilled the ACR criteria for the diagnosis of SLE. Tn the 3 yr of follow-up only three patients developed SLE. Conclusions, A high proportion of patients in our cohort defined on clinical grounds as having incomplete SLE eventually showed disease activity defined by the SLEDAI as well as ECLAM. However, only three cases developed to SLE during the follow-up. This suggests that incomplete SLE forms a subgroup of SLE that has a good prognosis.

Published
2001

9. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis

Author

Bohanec Grabar, P., Rozman, B., Logar, D., Praprotnik, S., and Dolzan, V.

Subjects
Oxidoreductases -- Research, Rheumatoid arthritis -- Care and treatment, Rheumatoid arthritis -- Patient outcomes, Rheumatoid arthritis -- Research, Leflunomide -- Dosage and administration, Leflunomide -- Complications and side effects, Leflunomide -- Research, Drugs -- Health aspects, Drugs -- Research, Health
Published
2009

10. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation

Author

Swaak, AJG van den Brink, HG Smeenk, RJT Manger, K and Kalden, JR Tosi, S Marchesoni, A Domljan, Z Rozman, B and Logar, D Pokorny, G Kovacs, L Kovacs, A and Vlachoyiannopoulos, PG Moutsopoulos, HM Chwalinska-Sadowska, H and Dratwianka, B Kiss, E Cikes, N Branimir, A and Schneider, M Fischer, R Bombardieri, S Mosca, M and Graninger, W Smolen, JS

Subjects
skin and connective tissue diseases
Abstract

Objective. Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of >10 yr. Methods. Outcome parameters were the SLE Disease Activity Index (SLEDAI); the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. Results. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (less than or equal to 7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of endorgan damage. Conclusions. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.

Published
1999

11. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation

Author

Swaak, A. J. G., van den Brink, H. G., Smeenk, R. J. T., Manger, K., Kalden, J. R., Tosi, S., Marchesoni, A., Domljan, Z., Rozman, B., Logar, D., Pokorny, G., Kovacs, L., Kovacs, A., Vlachoyiannopoulos, P. G., Moutsopoulos, H. M., Chwalinska-Sadowska, H., Dratwianka, B., Kiss, E., Cikes, N., Anić, Branimir, Schneider, M., Fischer, R., Bombardieri, S., Mosca, M., Graninger, W., and Smolen, J. S.

Subjects
systemic lupus, SLE, disease activity, SLEDAI, ECLAM, damage index, skin and connective tissue diseases
Abstract

Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of >10 yr. Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (≤7.5 mg). The cumulative damage was overall related to clinical features of the central nervous system (14%) and renal involvement (14%), next to deforming arthritis (14%), osteoporosis (15%) and hypertension (40%). The prevalences of obesity, Cushing appearance and diabetes are highly suggestive that the ongoing treatment and that in the past might have had an impact on the total sum of end-organ damage. After 10 yr, a high proportion of patients in our cohort continued to show evidence of active disease, defined by the SLEDAI as well as ECLAM. The DI was related to the involvement of the central nervous system, renal involvement and the presence of hypertension.

Published
1999

15. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)

Author

Swaak, A.J., Moutsopoulos, H.M., Dratwianka, B., Kalden, J.R., Tosi, S., Marchesoni, A., Vlachoyiannopoulos, P.G., Graninger, W., Cikes, N., Domljan, Z., Rozman, B., Chwalinska-Sadowska, H., Bombardieri, S., Kovacs, A., Schneider, M. (Peter), Logar, D., Kovacs, L., Smolen, J.S., Kiss, E., Pokorny, G., Brink, H. van de, Smeenk, R.J. (Ruud), Mosca, M., Anic, B., Manger, K., Fischer, R., Swaak, A.J., Moutsopoulos, H.M., Dratwianka, B., Kalden, J.R., Tosi, S., Marchesoni, A., Vlachoyiannopoulos, P.G., Graninger, W., Cikes, N., Domljan, Z., Rozman, B., Chwalinska-Sadowska, H., Bombardieri, S., Kovacs, A., Schneider, M. (Peter), Logar, D., Kovacs, L., Smolen, J.S., Kiss, E., Pokorny, G., Brink, H. van de, Smeenk, R.J. (Ruud), Mosca, M., Anic, B., Manger, K., and Fischer, R.

Abstract

OBJECTIVE: Patients characterized with antinuclear antibodies (ANA) and disease symptoms related to one organ system can be described as having incomplete systemic lupus erythematosus (SLE). The aim of this multicentre study was to describe the outcome of these so-called incomplete SLE patients. Two aspects of the outcome were studied: (i) the disease course, defined by the presence or absence of clinical symptoms; and (ii) the number of patients that eventually developed full SLE. METHODS: Outcome parameters were the ACR criteria, the SLE disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM) and the requirement for treatment. In 10 European rheumatology centres, patients who had been evaluated in the last 3 months of 1994 and had been diagnosed as having incomplete SLE on clinical grounds for at least 1 yr were included in the study. All 122 patients who were included in the study were evaluated annually during 3 yr of follow-up. RESULTS: Our results are confined to a patient cohort defined by disease duration of at least 1 yr, being under clinical care at the different centres in Europe. These patients showed disease activity that was related mostly to symptoms of the skin and the musculoskeletal system, and leucocytopenia. During the follow-up, low doses of prednisolone were still being prescribed in 43% of the patients. On recruitment to the study, 22 of the 122 incomplete SLE patients already fulfilled the ACR criteria for the diagnosis of SLE. In the 3 yr of follow-up only three patients developed SLE. CONCLUSIONS: A high proportion of patients in our cohort defined on clinical grounds as having incomplete SLE eventually showed disease activity defined by the SLEDAI as well as ECLAM. However, only three cases developed to SLE during the follow-up. This suggests that incomplete SLE forms a subgroup of SLE that has a good prognosis.

Published
2001

16. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation

Author

Swaak, A.J., Rozman, B., Chwalinska-Sadowska, H., Bombardieri, S., Kovacs, A., Schneider, M. (Peter), Logar, D., Kovacs, L., Kiss, E., Pokorny, G., Brink, H.G. van den, Smeenk, R.J. (Ruud), Mosca, M., Branimir, A., Manger, K., Dratwianka, B., Kalden, J.R., Tosi, S., Marchesoni, A., Moutsopoulos, H.M., Smolen, J.S., Cikes, N., Domljan, Z., Swaak, A.J., Rozman, B., Chwalinska-Sadowska, H., Bombardieri, S., Kovacs, A., Schneider, M. (Peter), Logar, D., Kovacs, L., Kiss, E., Pokorny, G., Brink, H.G. van den, Smeenk, R.J. (Ruud), Mosca, M., Branimir, A., Manger, K., Dratwianka, B., Kalden, J.R., Tosi, S., Marchesoni, A., Moutsopoulos, H.M., Smolen, J.S., Cikes, N., and Domljan, Z.

Abstract

OBJECTIVE: Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted to the first 5 yr after disease onset. Data about the disease course 10 yr after disease onset are rare. The aim of this multicentre study was to describe the outcome of SLE patients with a disease duration of >10 yr. METHODS: Outcome parameters were the SLE Disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM), the Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR), a global damage index (DI) and required treatment. In 10 different European rheumatology centres, all SLE patients who were evaluated in the last 3 months of 1994, and who had been diagnosed with SLE at least 10 yr ago, were included in the study. RESULTS: It should be stressed that our results are confined to a patient cohort, defined by a disease duration of at least 10 yr, and who are still under clinical care at the different centres in Europe. These SLE patients still showed some disease activity, related to symptoms of the skin and musculoskeletal systems, next to the presence of renal involvement. A total of 72% of the patients needed treatment with prednisolone (

Published
1999

17. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation

Author

Swaak, A JG, primary, van den Brink, H G, additional, Smeenk, R JT, additional, Manger, K, additional, Kalden, J R, additional, Tosi, S, additional, Domljan, Z, additional, Rozman, B, additional, Logar, D, additional, Pokorny, G, additional, Kovacs, L, additional, Kovacs, A, additional, Vlachoyiannopoulos, P G, additional, Moutsopoulos, H M, additional, Chwalinska-Sadowska, H, additional, Kiss, E, additional, Cikes, N, additional, Anic, B, additional, Schneider, M, additional, Fischer, R, additional, Bombardieri, S, additional, Mosca, M, additional, Graninger, W, additional, and Smolen, J S, additional

Published
2001
Full Text
View/download PDF

18. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation1

Author

Swaak, A. J. G., primary, van den Brink, H. G., additional, Smeenk, R. J. T., additional, Manger, K., additional, Kalden, J. R., additional, Tosi, S., additional, Marchesoni, A., additional, Domljan, Z., additional, Rozman, B., additional, Logar, D., additional, Pokorny, G., additional, Kovacs, L., additional, Kovacs, A., additional, Vlachoyiannopoulos, P. G., additional, Moutsopoulos, H. M., additional, Chwalinska-Sadowska, H., additional, Dratwianka, B., additional, Kiss, E., additional, Cikes, N., additional, Branimir, A., additional, Schneider, M., additional, Fischer, R., additional, Bombardieri, S., additional, Mosca, M., additional, Graninger, W., additional, and Smolen, J. S., additional

Published
1999
Full Text
View/download PDF

20. Prognostic Value of Contrast Enhanced Gd-DTPA MRI for Development of Bone Erosive Changes in Rheumatoid Arthritis

Author

Jevtic, V., primary, Watt, I., additional, Rozman, B., additional, Presetnik, M., additional, Logar, D., additional, Praprotnik, S., additional, Tomsic, M., additional, Sipek, A., additional, Kos-Golja, M., additional, Sepe, A., additional, Jarh, O., additional, Demsar, F., additional, Musikic, P., additional, and Campion, G., additional

Published
1996
Full Text
View/download PDF

25. Prognostic Value of Contrast Enhanced Gd-DTPA MRI for Development of Bone Erosive Changes in Rheumatoid Arthritis.

Author

Jevtic, V., Watt, I., Rozman, B., Presetnik, M., Logar, D., Praprotnik, S., Tomsic, M., Sipek, A., Kos-Golja, M., Sepe, A., Jarh, O., Demsar, F., Musikic, P., and Campion, G.

Abstract

Conventional radiograms have been used to quantitate the progression of rheumatoid arthritis, mainly through the assessment of bone erosions, but this approach has many limitations. It has been suggested that an advantage of contrast-enhanced Gd-DTPA MRI over radiography may be its prognostic value due to its ability to show the natural history of active destructive to inactive fibrous pannus. The aim of this study was to evaluate the possible prognostic value of MRI for future development of bone erosive changes in small hand joints in patients with RA. The results of the study confirm that in joints in which inflammatory active pannus is shown by contrast-enhanced MRI, progression of bone-destructive changes can be expected [ABSTRACT FROM PUBLISHER]

Published
1996
Full Text
View/download PDF

26. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)

Author

Swaak, A. J. G., van de Brink, H., Smeenk, R. J. T., Manger, K., Kalden, J. R., Tosi, S., Marchesoni, A., Domljan, Z., Rozman, B., Logar, D., Pokorny, G., Kovacs, L., Kovacs, A., Vlachoyiannopoulos, P. G., Moutsopoulos, H. M., Chwalinska‐Sadowska, H., Dratwianka, B., Kiss, E., Cikes, N., Anic, B., Schneider, M., Fischer, R., Bombardieri, S., Mosca, M., Graninger, W., and Smolen, J. S.

Abstract

Objective. Patients characterized with antinuclear antibodies (ANA) and disease symptoms related to one organ system can be described as having incomplete systemic lupus erythematosus (SLE). The aim of this multicentre study was to describe the outcome of these so‐called incomplete SLE patients. Two aspects of the outcome were studied: (i) the disease course, defined by the presence or absence of clinical symptoms; and (ii) the number of patients that eventually developed full SLE.Methods. Outcome parameters were the ACR criteria, the SLE disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM) and the requirement for treatment. In 10 European rheumatology centres, patients who had been evaluated in the last 3 months of 1994 and had been diagnosed as having incomplete SLE on clinical grounds for at least 1 yr were included in the study. All 122 patients who were included in the study were evaluated annually during 3 yr of follow‐up.Results. Our results are confined to a patient cohort defined by disease duration of at least 1 yr, being under clinical care at the different centres in Europe. These patients showed disease activity that was related mostly to symptoms of the skin and the musculoskeletal system, and leucocytopenia. During the follow‐up, low doses of prednisolone were still being prescribed in 43% of the patients. On recruitment to the study, 22 of the 122 incomplete SLE patients already fulfilled the ACR criteria for the diagnosis of SLE. In the 3 yr of follow‐up only three patients developed SLE.Conclusions. A high proportion of patients in our cohort defined on clinical grounds as having incomplete SLE eventually showed disease activity defined by the SLEDAI as well as ECLAM. However, only three cases developed to SLE during the follow‐up. This suggests that incomplete SLE forms a subgroup of SLE that has a good prognosis.

Published
2001

27. ARTERITIS OF BOTH CAROTID ARTERIES IN A PATIENT WITH FOCAL, CRESCENTIC GLOMERULONEPHRTTIS AND ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODIES.

Author

LOGAR, D., ROZMAN, B., VIZJAK, A., FERLUGA, D., MULDER, A. H. L., and KALLENBERG, C. G. M.

Abstract

We report a 32-yr-old woman who suffered a stroke as a consequence of arteritis of both internal carotid arteries confirmed by selective carotid arteriography. Laryngeal inflammation and kidney biopsy proven focal crescentic glomerulonephritis were also present in this patient. Anti-neutrophil cytoplasmic autoantibodies with specificity for proteinase 3 were detected in high titre during the active phase of the disease. This overlap syndrome with features indicating both Takayasu's arteritis and Wegener's granulomatosis suggests a common pathogenesis for these diseases. [ABSTRACT FROM PUBLISHER]

Published
1994
Full Text
View/download PDF

28. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.

Author

Bohanec Grabar P, Leandro-García LJ, Inglada-Pérez L, Logar D, Rodríguez-Antona C, and Dolžan V

Subjects
Aged, Arthritis, Rheumatoid genetics, Biomarkers, Pharmacological, Cell Line, Female, Genetic Association Studies, Haplotypes, Humans, Linkage Disequilibrium, Male, Middle Aged, Polymorphism, Single Nucleotide, Antirheumatic Agents administration & dosage, Antirheumatic Agents toxicity, Arthritis, Rheumatoid drug therapy, Methotrexate administration & dosage, Methotrexate toxicity, Reduced Folate Carrier Protein genetics
Abstract

Aim: We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach., Patients & Methods: Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation., Results: Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant., Conclusion: Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed.

Published
2012
Full Text
View/download PDF

29. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.

Author

Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, and Dolzan V

Subjects
Adult, Aged, Aged, 80 and over, Aniline Compounds therapeutic use, Antirheumatic Agents pharmacokinetics, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid metabolism, Aryl Hydrocarbon Hydroxylases physiology, Crotonates, Cytochrome P-450 CYP1A2 physiology, Cytochrome P-450 CYP2C19, Female, Humans, Hydroxybutyrates therapeutic use, Isoxazoles therapeutic use, Leflunomide, Male, Middle Aged, Nitriles, Synovial Membrane, Toluidines, Aniline Compounds pharmacokinetics, Arthritis, Rheumatoid blood, Aryl Hydrocarbon Hydroxylases genetics, Cytochrome P-450 CYP1A2 genetics, Hydroxybutyrates pharmacokinetics, Isoxazoles pharmacokinetics, Polymorphism, Genetic
Abstract

Leflunomide is a disease-modifying antirheumatic drug used for the treatment of rheumatoid arthritis (RA). Cytochromes P450, mainly CYP1A2 and CYP2C19, may be involved in the transformation of leflunomide to leflunomide metabolite (A77 1726, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide). The aim of this study was to investigate whether genetic polymorphisms in CYP1A2 and CYP2C19 influence leflunomide pharmacokinetics, treatment response, and the occurrence of adverse drug reactions (ADRs). The study included 67 patients with RA and 4 patients with polyarthritis resembling RA and psoriasis treated with leflunomide. A77 1726 steady-state plasma concentrations were determined by validated high-performance liquid chromatography with UV detection. A population pharmacokinetic model was developed to estimate the oral clearance (CL/F) and volume of distribution (V/F). A genotyping approach was used to determine C-163A, C-729T, and T-739G in the CYP1A2 gene as well as single nucleotide polymorphisms that characterize CYP2C19*2, *3, *4, and *17 alleles. A large interindividual variability in trough A77 1726 steady-state plasma concentrations was observed (from 1.9 to 156.9 mg/l). A77 1726 CL/F was 71% higher in carriers of the CYP2C19*2 allele compared with noncarriers. The A77 1726 average steady-state plasma concentration was associated with the treatment response. Patients with a greater decrease in C-reactive protein (CRP) had higher average steady-state plasma A77 1726 concentrations: 49.7 +/- 39.0 mg/l in patients with DeltaCRP of more than 8.5 mg/l compared with 24.8 +/- 13.7 mg/l in patients with DeltaCRP of

Published
2009
Full Text
View/download PDF

30. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis.

Author

Bohanec Grabar P, Logar D, Tomsic M, Rozman B, and Dolzan V

Subjects
Aged, Female, Genotype, Glutathione S-Transferase pi genetics, Humans, Male, Middle Aged, Severity of Illness Index, Smoking adverse effects, Arthritis, Rheumatoid genetics, Glutathione Transferase genetics, Polymorphism, Single Nucleotide, Smoking genetics
Abstract

Objectives: Glutathione S-transferases (GST); GST-mu1 (GSTM1), GST-pi1 (GSTP1) and GST-theta1 (GSTT1) have peroxidase activity towards cytotoxic metabolites produced in inflammatory reactions, the main feature of rheumatoid arthritis (RA). Genetic polymorphisms in GSTM1, GSTP1 and GSTT1 modify the enzyme conjugation capacity and may be associated with the activity of RA., Methods: A genotyping approach was used to analyze GSTM1-0, GSTT1-0 and GSTP1 Ile105Val and Ala114Val polymorphisms in 213 RA patients. Disease activity was assessed by the disease activity score of 28 joint counts (DAS28) twice for each patient and mean DAS28 values were calculated., Results: The patients with GSTT1-0 genotype had a higher risk for developing high activity RA than the patients with GSTT1 genes present (p=0.028, OR=2.761, 95% CI=1.114-6.843). An interaction between the GSTT1 polymorphism and smoking was observed. In the group of smokers, the carriers of a homozygous deletion GSTT1 had an 8.5-fold higher risk for developing high disease activity than the patients with the GSTT1-1 genotype (p=0.004, OR=8.640, 95% CI=1.995-37.426). GSTM1 and GSTP1 polymorphisms were not associated with the disease activity., Conclusion: Our results suggest that the presence of the GSTT1-0 genotype contributed to higher disease activity in RA patients. The risk for developing highly active RA was the highest in smokers with the GSTT1-0 genotype.

Published
2009

31. Genetic polymorphisms modifying oxidative stress are associated with disease activity in rheumatoid arthritis patients.

Author

Bohanec Grabar P, Logar D, Tomsic M, Rozman B, and Dolzan V

Subjects
Amino Acid Substitution, Arthritis, Rheumatoid pathology, Base Sequence, Catalase genetics, DNA Primers genetics, Female, Genetic Markers, Humans, Male, Microsatellite Repeats, Middle Aged, Minisatellite Repeats, Nitric Oxide Synthase Type II genetics, Polymorphism, Single Nucleotide, Superoxide Dismutase genetics, Tumor Necrosis Factor-alpha genetics, Arthritis, Rheumatoid genetics, Arthritis, Rheumatoid metabolism, Oxidative Stress genetics, Polymorphism, Genetic
Abstract

Reactive oxygen and nitrogen species are involved in the pathology of rheumatoid arthritis (RA). Polymorphisms in genes coding for superoxide dismutases (SOD2 and SOD3), catalase (CAT), tumor necrosis factor-alpha (TNFA) and inducible NO synthase (NOS2A) may influence RA activity. We determined SOD2 Ala-9Val, SOD3 Arg213Gly, CAT C-262T, TNFA G-308A, TNFA C-857T and NOS2A (CCTTT) (n)polymorphisms in 327 RA patients. Carriers of CAT -262T and TNFA -308A allele had lower mean disease activity score of 28 joint count (DAS28) values than patients with CAT -262CC and TNFA -308GG genotypes (p = 0.014 and p = 0.046, respectively). Patients with the combination of CAT -262T and TNFA -308A allele had lower mean DAS28 values and a higher probability for low disease activity than non-carriers (p = 0.003, OR = 3.585, 95% CI = 1.538-8.357). Our results suggest that CAT and TNFA polymorphisms alone and in combination influence the activity of RA.

Published
2009
Full Text
View/download PDF

32. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism.

Author

Bohanec Grabar P, Logar D, Lestan B, and Dolzan V

Subjects
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase genetics, ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Aged, Biological Transport, Female, Ferredoxin-NADP Reductase genetics, Humans, Male, Membrane Transport Proteins genetics, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Middle Aged, Thymidylate Synthase genetics, Arthritis, Rheumatoid drug therapy, Folic Acid metabolism, Methotrexate metabolism, Methotrexate toxicity, Polymorphism, Genetic
Abstract

Objective: Methotrexate (MTX) is a disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis (RA). Genetic polymorphisms of reduced folate carrier (RFC1 A80G), P-glycoprotein (MDR1 G2677T>A/C and C3435T), 5,10-methylenetetrahydrofolate reductase (MTHFR C677T and A1298C), thymidylate synthase (TS 2R-->3R), methionine synthase (MS A2756G) and methionine synthase reductase (MTRR A66G) modify MTX transport and metabolic effects and may influence the treatment response., Methods: A genotyping approach was used to determine the studied polymorphisms in 213 RA patients., Results: We observed that 56 (26.3%) patients discontinued MTX treatment due to poor response and/or toxicity. RFC1 A80G and MDR1 C3435T polymorphisms increased the risk for overall MTX toxicity (P = 0.039, OR = 3.574, 95% CI = 1.065-11.993 and P = 0.032, OR = 7.801, 95% CI = 1.194-50.960 respectively), while MTHFR A1298C polymorphism had a protective effect on overall MTX toxicity (P = 0.027, OR = 0.170, 95% CI = 0.035-0.820)., Conclusion: Our results suggest that genetic polymorphisms in the folate metabolic pathway and MTX transporters modify the toxicity but not the efficacy of MTX treatment.

Published
2008
Full Text
View/download PDF

33. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.

Author

Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, and Dolzan V

Subjects
Aged, Diarrhea chemically induced, Dose-Response Relationship, Drug, Female, Humans, Leflunomide, Male, Middle Aged, Nausea chemically induced, Pharmacogenetics, Pilot Projects, Pruritus chemically induced, Vomiting chemically induced, Antirheumatic Agents toxicity, Arthritis, Rheumatoid drug therapy, Cytochrome P-450 CYP1A2 genetics, Isoxazoles toxicity, Polymorphism, Genetic
Abstract

Objective: Leflunomide is a disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA). In vitro studies demonstrated that cytochromes P450 (CYPs), mainly CYP1A2 and CYP2C19, might be involved in leflunomide activation. The aim of our study was to investigate whether genetic polymorphisms of CYP1A2, CYP2C19, and CYP2C9 influence leflunomide toxicity., Methods: A genotyping approach was used to determine CYP1A2*1F, CYP2C19*2, CYP2C19*17, CYP2C9*2, and CYP2C9*3 alleles in 105 RA patients., Results: Leflunomide treatment was well tolerated by 62 patients, whereas 43 patients discontinued the treatment within the first year due to toxicity. Patients with CYP1A2*1F CC genotype had a 9.7-fold higher risk for overall leflunomide-induced toxicity than did the carriers of CYP1A2*1F A allele [P = 0.002, odds ratio = 9.708, 95% confidence interval = 2.276-41.403]. No significant association between the CYP2C19 and CYP2C9 genotypes and the leflunomide toxicity was observed., Conclusion: Our results suggest that the CYP1A2*1F allele may be associated with leflunomide toxicity in RA patients.

Published
2008
Full Text
View/download PDF

34. Subcutaneous infection with Pseudallescheria boydii in an immunocompromised patient.

Author

Lainscak M, Hocevar A, Logar D, Beović B, Matos T, and Tomsic M

Subjects
Humans, Male, Middle Aged, Pseudallescheria pathogenicity, Vasculitis drug therapy, Vasculitis microbiology, Anti-Inflammatory Agents adverse effects, Immunocompromised Host, Methylprednisolone adverse effects, Mycetoma immunology, Pseudallescheria immunology
Abstract

With the broad employment of immunosuppressive therapy, the incidence of Pseudallescheria boydii infections is rising. We report a first case of the localized subcutaneous P. boydii infection in a patient with microscopic polyangiitis. Favorable outcome related to the treatment with voriconazole adds to the growing body of evidence supporting the use of this particular agent in P. boydii infections.

Published
2007
Full Text
View/download PDF

35. Recurrent sepsis and seronegative arthritis in a patient with a selective IgG3 deficiency.

Author

Ambrozic J, Logar D, Stajer D, Gorjup V, Golja MK, and Horvat M

Subjects
Arthritis immunology, Chronic Disease, Diabetes Mellitus, Type 2 complications, Diagnosis, Differential, Enzyme-Linked Immunosorbent Assay, Female, Humans, IgG Deficiency complications, IgG Deficiency immunology, Middle Aged, Recurrence, Remission Induction, Arthritis complications, IgG Deficiency diagnosis, Immunoglobulin G blood, Sepsis immunology
Abstract

In a sixty-one-year-old patient with chronic polyarthritis, two life-threatening septic events were observed over a period of 6 months. The patient also had a selective IgG3 deficiency. The susceptibility to infection and chronic polyarthritis observed in this patient were very likely a consequence of the selective IgG3 deficiency.

Published
2000

36. Contrast enhanced Gd-DTPA magnetic resonance imaging in the evaluation of rheumatoid arthritis during a clinical trial with DMARDs. A prospective two-year follow-up study on hand joints in 31 patients.

Author

Jevtic V, Watt I, Rozman B, Kos-Golja M, Praprotnik S, Logar D, Presetnik M, Demsar F, Jarh O, Campion G, and Musikic P

Subjects
Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid pathology, Bone and Bones diagnostic imaging, Bone and Bones pathology, Contrast Media, Double-Blind Method, Evaluation Studies as Topic, Female, Follow-Up Studies, Gadolinium, Hand pathology, Humans, Isoxazoles therapeutic use, Joints drug effects, Joints pathology, Leflunomide, Male, Middle Aged, Pain pathology, Pentetic Acid analogs & derivatives, Phosphatidylethanolamines, Radiography, Radionuclide Imaging, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnosis, Gadolinium DTPA, Hand diagnostic imaging, Joints diagnostic imaging, Magnetic Resonance Imaging methods
Abstract

Objective: The aim of this prospective 24-month follow-up study was to compare clinical features with radiological and magnetic resonance imaging (MRI) findings in evaluating synovial proliferation in the hand joints of 31 patients with rheumatoid arthritis (RA). A single joint was used for the follow-up of each patient., Methods: Thirty-one small hand joints were examined by conventional radiography and MRI before and after 24 months of treatment. MRI assessment of disease progression (volume and/or signal intensity of the synovial proliferation on T1 weighted precontrast, T1 weighted postcontrast and T2 weighted images) was compared with a clinical assessment of the chosen joints, and with a plain x-ray film evaluation (Larsen's score)., Results: Of 26 joints which clinically improved (14 markedly and 14 slightly) during the study, on MRI 16 showed improvement, 8 showed no change, and 2 showed deterioration. Four clinically unchanged joints appeared improved on MRI. One joint deteriorated clinically and on MRI. Overall, there was a 58% congruence between clinical and MRI findings. On x-ray 23 joints showed no change; nine of these were also unchanged on MRI, while 13 showed improvement and one deterioration. Only in 2 out of 8 joints showing deterioration on x-ray were the MRI findings in accordance. In the remaining six joints MRI showed improvement. The congruence between x-ray and MRI was therefore 36%., Conclusion: The long-term follow-up of rheumatoid synovial proliferation of the small joints in the hand using contrast enhanced MRI is feasible and may provide additional information regarding disease activity. Important advantages over conventional radiography methods are its ability to demonstrate qualitative differences of synovial proliferation within bone erosions, and demonstrate not only deterioration, but also the improvement of inflammatory disease.

Published
1997

37. [Gold salt alveolitis in 3 patients with rheumatoid arthritis].

Author

Music E, Tomsic M, and Logar D

Subjects
Aged, Auranofin administration & dosage, Biopsy, Bronchoalveolar Lavage Fluid, Female, Gold Sodium Thiomalate administration & dosage, Humans, Male, Middle Aged, Pulmonary Alveoli pathology, Pulmonary Fibrosis diagnostic imaging, Pulmonary Fibrosis pathology, Radiography, Arthritis, Rheumatoid drug therapy, Auranofin adverse effects, Gold Sodium Thiomalate adverse effects, Pulmonary Fibrosis chemically induced
Abstract

Background: When the characteristic symptoms for an interstitial pulmonary disease arise in patients with rheumatoid arthritis, a drug-induced alveolitis should be considered in the differential diagnosis. In such cases, the administration of the drug and gold salts should be stopped., Patients and Methods: The cases of three patients with rheumatoid arthritis (RA) who had been treated with gold salts for 2 months (A), 23 months (B), and 36 months (C) are presented. The total dose of sodium aureothiomalate amounted to 280 mg for patient A, 1150 mg for patient B, and 2190 mg for patient C. Clinical signs, X-rays of the lungs, pulmonary function tests, and laboratory tests were evaluated for the three patients while, for patient A BAL as well as provocation tests were additionally performed before and after therapy. In this case, the histological picture of the lungs is presented; biopsies were taken during the first BAL., Results: The clinical complaints of all 3 patients were similar, with the alveolitis being observed as diffuse in one case and above all in the upper regions in two cases on radiology. This led to differing degrees of diffusion disorders in the lungs. In patient A, the diagnosis was made in the stage of progressive fibrotic alveolitis and was treated with D-penicillamine. All 3 patients received steroids over 3-6 months and the gold salts were stopped. Because of the long duration and doubtful differential diagnosis for patient A with either rheumatoid lung or gold salt alveolitis, a provocation test with sodium aureothiomalate was performed. All 3 patients had blood eosinophilia while, in case A, a thrombopenia was also found., Conclusions: A gold salt alveolitis can occur as a side effect of gold salts in addition to skin vasculitis and hematological disorders. When the gold salt administration is not stopped a fibrotic alveolitis can develop. The provocation test can be diagnostically useful to distinguish between a rheumatoid lung and gold salt alveolitis.

Published
1995

38. The dissociation of arterial hypertension and lupus glomerulonephritis in systemic lupus erythematosus.

Author

Petrin J, Rozman B, Dolenc P, Logar D, Bozic B, Vizjak A, Ferluga D, and Jezersek P

Subjects
Adolescent, Adult, Antibodies, Anticardiolipin blood, Blood Pressure physiology, Child, Female, Humans, Hypertension pathology, Hypertension physiopathology, Kidney pathology, Lupus Erythematosus, Systemic physiopathology, Lupus Nephritis pathology, Male, Middle Aged, Retrospective Studies, Hypertension etiology, Lupus Erythematosus, Systemic complications, Lupus Nephritis complications
Abstract

In spite of several articles questioning the general opinion that arterial hypertension in patients with systemic lupus erythematosus (SLE) is only the consequence of lupus glomerulonephritis (LGN), this still remains the usual pathophysiologic explanation. The purpose of this study was to explore the correlations between hypertension and LGN and to assess the importance of hypertension control for the prognosis of patients. A retrospective analysis of 173 patients with SLE over a period of 14 years was performed. For most of the patients, data were available from regular follow-up visits over an average of 6 years. Our results show a dissociation of hypertension and LGN and an association of hypertension and renal dysfunction. Severe hypertensive renal vascular lesions correlated well with a decrease of renal function. Successful treatment of hypertension is therefore essential in order to prevent deterioration of renal function in patients with LGN.

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results